Lynx Posts Sharply Lowered Q2 Revenue, Widened Loss

Aug 01, 2002

NEW YORK, Aug. 1 - Lynx Therapeutics yesterday reported that despite lighter R&D spending and a workforce reduction that cost 60 staffers their jobs, second-quarter net loss continued to widen as revenues fell sharply.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

To Control the Spread

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

Main menu